Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 400

1.

A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic patients previously treated with both chemotherapy and pazopanib.

Penel N, Mir O, Wallet J, Ray-Coquard I, Le Cesne A, Italiano A, Salas S, Delcambre C, Bompas E, Bertucci F, Saada-Bouzid E, Chaigneau L, Chevreau C, Brodowicz T, Decoupigny E, Vanseymortier M, Laroche L, Taieb S, Le Deley MC, Blay JY.

Eur J Cancer. 2020 Jan 6;126:45-55. doi: 10.1016/j.ejca.2019.12.001. [Epub ahead of print]

PMID:
31918233
2.

Overexpression of Annexin A1 Is an Independent Predictor of Longer Overall Survival in Epithelial Ovarian Cancer.

Manai M, Doghri R, Finetti P, Mrad K, Bouabsa R, Manai M, Birnbaum D, Bertucci F, Charfi L, Driss M.

In Vivo. 2020 Jan-Feb;34(1):177-184. doi: 10.21873/invivo.11759.

PMID:
31882477
3.

NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.

Bertucci F, Rypens C, Finetti P, Guille A, Adelaïde J, Monneur A, Carbuccia N, Garnier S, Dirix P, Gonçalves A, Vermeulen P, Debeb BG, Wang X, Dirix L, Ueno NT, Viens P, Cristofanilli M, Chaffanet M, Birnbaum D, Van Laere S.

Mol Oncol. 2019 Dec 19. doi: 10.1002/1878-0261.12621. [Epub ahead of print]

4.

A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study).

Pautier P, Penel N, Ray-Coquard I, Italiano A, Bompas E, Delcambre C, Bay JO, Bertucci F, Delaye J, Chevreau C, Cupissol D, Bozec L, Eymard JC, Saada E, Isambert N, Guillemet C, Rios M, Piperno-Neumann S, Chenuc G, Duffaud F.

Eur J Cancer. 2020 Jan;125:31-37. doi: 10.1016/j.ejca.2019.10.028. Epub 2019 Dec 10.

PMID:
31835236
5.

Impact of Metastasis Surgery and Alkylating-Agent-Based Chemotherapy on Outcomes of Metastatic Malignant Phyllodes Tumors: A Multicenter Retrospective Study.

Neron M, Sajous C, Thezenas S, Piperno-Neumann S, Reyal F, Laé M, Chakiba C, Penel N, Ryckewaert T, Honoré C, Bertucci F, Monneur A, Salas S, Duffaud F, Saada-Bouzid E, Isambert N, Brahmi M, Ray-Coquard I, Blay JY, Firmin N; French Sarcoma Group (GSF-GETO).

Ann Surg Oncol. 2019 Nov 26. doi: 10.1245/s10434-019-08097-x. [Epub ahead of print]

PMID:
31773519
6.

MARCKS protein overexpression is associated with poor prognosis in male breast cancer.

Manai M, Abdeljaoued S, Goucha A, Adouni O, Bettaieb I, Bouzaien H, Rahal K, Birnbaum D, Bertucci F, Gamoudi A.

Cancer Biomark. 2019;26(4):513-522. doi: 10.3233/CBM-190637.

PMID:
31771045
7.

PDL1 expression is associated with longer postoperative, survival in adrenocortical carcinoma.

Billon E, Finetti P, Bertucci A, Niccoli P, Birnbaum D, Mamessier E, Bertucci F.

Oncoimmunology. 2019 Aug 28;8(11):e1655362. doi: 10.1080/2162402X.2019.1655362. eCollection 2019.

PMID:
31646101
8.

Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation.

Garciaz S, N'guyen Dasi L, Finetti P, Chevalier C, Vernerey J, Poplineau M, Platet N, Audebert S, Pophillat M, Camoin L, Bertucci F, Calmels B, Récher C, Birnbaum D, Chabannon C, Vey N, Duprez E.

Clin Epigenetics. 2019 Oct 12;11(1):141. doi: 10.1186/s13148-019-0738-6.

9.

Successful Imatinib Treatment of an Abdominal Compartment Syndrome due to Huge Gastrointestinal Stromal Tumour.

Bertucci A, Guiramand J, Mescam L, Monneur A, Bisbal M, Chow-Chine L, Sannini A, Perrot D, De Luca V, Mokart D, Bertucci F.

Case Rep Oncol. 2019 Aug 13;12(2):644-649. doi: 10.1159/000502338. eCollection 2019 May-Aug.

10.

Effects of Asparagopsis taxiformis metabolites on the feeding behaviour of post-larval Acanthurus triostegus.

Gache C, Bertucci F, Guerra AS, Calandra M, Berr T, Lafaye J, Jorissen H, Nugues M, Cossy J, Lecchini D.

J Fish Biol. 2019 Nov;95(5):1355-1358. doi: 10.1111/jfb.14140. Epub 2019 Oct 14.

PMID:
31568585
11.

[E-health and "Cancer outside the hospital walls", Big Data and artificial intelligence].

Bertucci F, Le Corroller-Soriano AG, Monneur A, Fluzin S, Viens P, Maraninchi D, Goncalves A.

Bull Cancer. 2019 Sep 19. pii: S0007-4551(19)30297-8. doi: 10.1016/j.bulcan.2019.07.006. [Epub ahead of print] Review. French.

PMID:
31543271
12.

A genome-wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells.

Arfaoui A, Rioualen C, Azzoni V, Pinna G, Finetti P, Wicinski J, Josselin E, Macario M, Castellano R, Léonard-Stumpf C, Bal A, Gros A, Lossy S, Kharrat M, Collette Y, Bertucci F, Birnbaum D, Douik H, Bidaut G, Charafe-Jauffret E, Ginestier C.

EMBO Mol Med. 2019 Oct;11(10):e9930. doi: 10.15252/emmm.201809930. Epub 2019 Sep 2.

13.

Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study.

Le Cesne A, Marec-Berard P, Blay JY, Gaspar N, Bertucci F, Penel N, Bompas E, Cousin S, Toulmonde M, Bessede A, Fridman WH, Sautes-Fridman C, Kind M, Le Loarer F, Pulido M, Italiano A.

Eur J Cancer. 2019 Sep;119:151-157. doi: 10.1016/j.ejca.2019.07.018. Epub 2019 Aug 21.

PMID:
31442817
14.

A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers.

de Nonneville A, Finetti P, Adelaide J, Lambaudie É, Viens P, Gonçalves A, Birnbaum D, Mamessier E, Bertucci F.

Cancers (Basel). 2019 Aug 13;11(8). pii: E1158. doi: 10.3390/cancers11081158.

15.

PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review.

Planes-Laine G, Rochigneux P, Bertucci F, Chrétien AS, Viens P, Sabatier R, Gonçalves A.

Cancers (Basel). 2019 Jul 22;11(7). pii: E1033. doi: 10.3390/cancers11071033. Review.

16.

Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study.

Toulmonde M, Pulido M, Ray-Coquard I, Andre T, Isambert N, Chevreau C, Penel N, Bompas E, Saada E, Bertucci F, Lebbe C, Le Cesne A, Soulie P, Piperno-Neumann S, Sweet S, Cecchi F, Hembrough T, Bellera C, Kind M, Crombe A, Lucchesi C, Le Loarer F, Blay JY, Italiano A.

Lancet Oncol. 2019 Sep;20(9):1263-1272. doi: 10.1016/S1470-2045(19)30276-1. Epub 2019 Jul 19.

PMID:
31331699
17.

Author Correction: Genomic characterization of metastatic breast cancers.

Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, Soria JC, Dien AT, Adnani Y, Kamal M, Garnier S, Meurice G, Jimenez M, Dogan S, Verret B, Chaffanet M, Bachelot T, Campone M, Lefeuvre C, Bonnefoi H, Dalenc F, Jacquet A, De Filippo MR, Babbar N, Birnbaum D, Filleron T, Le Tourneau C, André F.

Nature. 2019 Aug;572(7767):E7. doi: 10.1038/s41586-019-1380-3.

PMID:
31308536
18.

Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome-09 study.

Piperno-Neumann S, Ray-Coquard I, Occean BV, Laurence V, Cupissol D, Perrin C, Penel N, Bompas E, Rios M, Le Cesne A, Italiano A, Anract P, de Pinieux G, Collard O, Bertucci F, Duffaud F, Le Deley MC, Delaye J, Brugieres L, Blay JY.

Int J Cancer. 2020 Jan 15;146(2):413-423. doi: 10.1002/ijc.32526. Epub 2019 Jul 19.

PMID:
31246277
19.

Can we cure patients with abdominal Desmoplastic Small Round Cell Tumor? Results of a retrospective multicentric study on 100 patients.

Honoré C, Delhorme JB, Nassif E, Faron M, Ferron G, Bompas E, Glehen O, Italiano A, Bertucci F, Orbach D, Pocard M, Quenet F, Blay JY, Carrere S, Chevreau C, Mir O, Le Cesne A; French Network for Rare Peritoneal Malignancies (RENAPE), French Sarcoma Clinical Network (NETSARC).

Surg Oncol. 2019 Jun;29:107-112. doi: 10.1016/j.suronc.2019.04.002. Epub 2019 Apr 15.

PMID:
31196472
20.

Sensitive and easy screening for circulating tumor cells by flow cytometry.

Lopresti A, Malergue F, Bertucci F, Liberatoscioli ML, Garnier S, DaCosta Q, Finetti P, Gilabert M, Raoul JL, Birnbaum D, Acquaviva C, Mamessier E.

JCI Insight. 2019 Jun 13;5. pii: 128180. doi: 10.1172/jci.insight.128180.

21.

Surgery in reference centers improves survival of sarcoma patients: a nationwide study.

Blay JY, Honoré C, Stoeckle E, Meeus P, Jafari M, Gouin F, Anract P, Ferron G, Rochwerger A, Ropars M, Carrere S, Marchal F, Sirveaux F, Di Marco A, Le Nail LR, Guiramand J, Vaz G, Machiavello JC, Marco O, Causeret S, Gimbergues P, Fiorenza F, Chaigneau L, Guillemin F, Guilloit JM, Dujardin F, Spano JP, Ruzic JC, Michot A, Soibinet P, Bompas E, Chevreau C, Duffaud F, Rios M, Perrin C, Firmin N, Bertucci F, Le Pechoux C, Le Loarer F, Collard O, Karanian-Philippe M, Brahmi M, Dufresne A, Dupré A, Ducimetière F, Giraud A, Pérol D, Toulmonde M, Ray-Coquard I, Italiano A, Le Cesne A, Penel N, Bonvalot S.

Ann Oncol. 2019 Aug 1;30(8):1407. doi: 10.1093/annonc/mdz170. No abstract available.

22.

Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease.

Mari R, Mamessier E, Lambaudie E, Provansal M, Birnbaum D, Bertucci F, Sabatier R.

Cancers (Basel). 2019 Jun 4;11(6). pii: E774. doi: 10.3390/cancers11060774. Review.

23.

PARP1 expression in soft tissue sarcomas is a poor-prognosis factor and a new potential therapeutic target.

Bertucci F, Finetti P, Monneur A, Perrot D, Chevreau C, Le Cesne A, Blay JY, Mir O, Birnbaum D.

Mol Oncol. 2019 Jul;13(7):1577-1588. doi: 10.1002/1878-0261.12522. Epub 2019 Jun 7.

24.

Genomic characterization of metastatic breast cancers.

Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, Soria JC, Dien AT, Adnani Y, Kamal M, Garnier S, Meurice G, Jimenez M, Dogan S, Verret B, Chaffanet M, Bachelot T, Campone M, Lefeuvre C, Bonnefoi H, Dalenc F, Jacquet A, De Filippo MR, Babbar N, Birnbaum D, Filleron T, Le Tourneau C, André F.

Nature. 2019 May;569(7757):560-564. doi: 10.1038/s41586-019-1056-z. Epub 2019 May 22. Erratum in: Nature. 2019 Aug;572(7767):E7.

PMID:
31118521
25.

A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases.

Tyran M, Carbuccia N, Garnier S, Guille A, Adelaïde J, Finetti P, Toulzian J, Viens P, Tallet A, Goncalves A, Metellus P, Birnbaum D, Chaffanet M, Bertucci F.

Cancers (Basel). 2019 May 13;11(5). pii: E665. doi: 10.3390/cancers11050665.

26.

Surgery in reference centers improves survival of sarcoma patients: a nationwide study.

Blay JY, Honoré C, Stoeckle E, Meeus P, Jafari M, Gouin F, Anract P, Ferron G, Rochwerger A, Ropars M, Carrere S, Marchal F, Sirveaux F, Di Marco A, Le Nail LR, Guiramand J, Vaz G, Machiavello JC, Marco O, Causeret S, Gimbergues P, Fiorenza F, Chaigneau L, Guillemin F, Guilloit JM, Dujardin F, Spano JP, Ruzic JC, Michot A, Soibinet P, Bompas E, Chevreau C, Duffaud F, Rios M, Perrin C, Firmin N, Bertucci F, Le Pechoux C, Le Loarer F, Collard O, Karanian-Philippe M, Brahmi M, Dufresne A, Dupré A, Ducimetière F, Giraud A, Pérol D, Toulmonde M, Ray-Coquard I, Italiano A, Le Cesne A, Penel N, Bonvalot S; NETSARC/REPPS/RESOS and French Sarcoma Group–Groupe d’Etude des Tumeurs Osseuses (GSF-GETO) Networks.

Ann Oncol. 2019 Jul 1;30(7):1143-1153. doi: 10.1093/annonc/mdz124. Erratum in: Ann Oncol. 2019 Jun 05;:.

27.

Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer.

Sabatier R, Charafe-Jauffret E, Pierga JY, Curé H, Lambaudie E, Genre D, Houvenaeghel G, Viens P, Ginestier C, Bertucci F, Sfumato P, Extra JM, Gonçalves A.

J Clin Med. 2019 May 6;8(5). pii: E612. doi: 10.3390/jcm8050612.

28.

XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma.

Birnbaum DJ, Finetti P, Birnbaum D, Mamessier E, Bertucci F.

J Clin Med. 2019 Apr 30;8(5). pii: E596. doi: 10.3390/jcm8050596.

29.

ECT2 associated to PRICKLE1 are poor-prognosis markers in triple-negative breast cancer.

Daulat AM, Finetti P, Revinski D, Silveira Wagner M, Camoin L, Audebert S, Birnbaum D, Kodjabachian L, Borg JP, Bertucci F.

Br J Cancer. 2019 Apr;120(9):931-940. doi: 10.1038/s41416-019-0448-z. Epub 2019 Apr 11.

30.

Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors.

Birnbaum DJ, Bertucci F, Finetti P, Birnbaum D, Mamessier E.

Cancers (Basel). 2019 Apr 8;11(4). pii: E497. doi: 10.3390/cancers11040497.

31.

Sarcomas in patients over 90: Natural history and treatment-A nationwide study over 6 years.

Basse C, Italiano A, Penel N, Mir O, Chemin C, Toulmonde M, Duffaud F, Le Cesne A, Chevreau C, Maynou C, Anract P, Gouin F, Rios M, Firmin N, Kurtz JE, Kerbrat P, Piperno-Neumann S, Bertucci F, Rosset P, Isambert N, Bompas E, Dubray-Longeras P, Fiorenza F, Le Maignan C, Chaigneau L, Thyss A, Bouché O, Eymard JC, Delcambre Lair C, Adam J, Karanian M, Lebbé C, Dupré A, Meeus P, Brahmi M, Dufresne A, Ducimetière F, Ray-Coquard I, Blay JY.

Int J Cancer. 2019 Oct 15;145(8):2135-2143. doi: 10.1002/ijc.32307. Epub 2019 Apr 15.

32.

Validation of Neutrophil Count as An Algorithm-Based Predictive Factor of Progression-Free Survival in Patients with Metastatic Soft Tissue Sarcomas Treated with Trabectedin.

de Nonneville A, Barbolosi D, Andriantsoa M, El-Cheikh R, Duffaud F, Bertucci F, Salas S.

Cancers (Basel). 2019 Mar 26;11(3). pii: E432. doi: 10.3390/cancers11030432.

33.

Simultaneous production of two kinds of sounds in relation with sonic mechanism in the boxfish Ostracion meleagris and O. cubicus.

Parmentier E, Solagna L, Bertucci F, Fine ML, Nakae M, Compère P, Smeets S, Raick X, Lecchini D.

Sci Rep. 2019 Mar 21;9(1):4962. doi: 10.1038/s41598-019-41198-x.

34.

Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer.

Xiao Y, Ma D, Zhao S, Suo C, Shi J, Xue MZ, Ruan M, Wang H, Zhao J, Li Q, Wang P, Shi L, Yang WT, Huang W, Hu X, Yu KD, Huang S, Bertucci F, Jiang YZ, Shao ZM; AME Breast Cancer Collaborative Group.

Clin Cancer Res. 2019 Aug 15;25(16):5002-5014. doi: 10.1158/1078-0432.CCR-18-3524. Epub 2019 Mar 5.

PMID:
30837276
35.

ESR1 mutations in metastatic lobular breast cancer patients.

Desmedt C, Pingitore J, Rothé F, Marchio C, Clatot F, Rouas G, Richard F, Bertucci F, Mariani O, Galant C, Fribbens C, O'Leary B, van den Eynden G, Salgado R, Turner NC, Piccart M, Vincent-Salomon A, Pruneri G, Larsimont D, Sotiriou C.

NPJ Breast Cancer. 2019 Feb 22;5:9. doi: 10.1038/s41523-019-0104-z. eCollection 2019.

36.

Evaluation of microplastic ingestion by tropical fish from Moorea Island, French Polynesia.

Garnier Y, Jacob H, Guerra AS, Bertucci F, Lecchini D.

Mar Pollut Bull. 2019 Mar;140:165-170. doi: 10.1016/j.marpolbul.2019.01.038. Epub 2019 Jan 25.

PMID:
30803630
37.

Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression.

Van Berckelaer C, Rypens C, van Dam P, Pouillon L, Parizel M, Schats KA, Kockx M, Tjalma WAA, Vermeulen P, van Laere S, Bertucci F, Colpaert C, Dirix L.

Breast Cancer Res. 2019 Feb 18;21(1):28. doi: 10.1186/s13058-019-1108-1.

38.

Localized high grade endometrial stromal sarcoma and localized undifferentiated uterine sarcoma: a retrospective series of the French Sarcoma Group.

Meurer M, Floquet A, Ray-Coquard I, Bertucci F, Auriche M, Cordoba A, Piperno-Neumann S, Salas S, Delannes M, Chevalier T, Italiano A, Blay JY, Mancini J, Pautier P, Duffaud F.

Int J Gynecol Cancer. 2019 May;29(4):691-698. doi: 10.1136/ijgc-2018-000064. Epub 2019 Feb 16.

PMID:
30772825
39.

ProNGF increases breast tumor aggressiveness through functional association of TrkA with EphA2.

Lévêque R, Corbet C, Aubert L, Guilbert M, Lagadec C, Adriaenssens E, Duval J, Finetti P, Birnbaum D, Magné N, Chopin V, Bertucci F, Le Bourhis X, Toillon RA.

Cancer Lett. 2019 May 1;449:196-206. doi: 10.1016/j.canlet.2019.02.019. Epub 2019 Feb 13.

PMID:
30771434
40.

Outpatient Cancer Care Delivery in the Context of E-Oncology: A French Perspective on "Cancer outside the Hospital Walls".

Bertucci F, Le Corroller-Soriano AG, Monneur-Miramon A, Moulin JF, Fluzin S, Maraninchi D, Gonçalves A.

Cancers (Basel). 2019 Feb 14;11(2). pii: E219. doi: 10.3390/cancers11020219.

41.

Inflammatory breast cancer in 210 patients: A retrospective study on epidemiological, anatomo-clinical features and therapeutic results.

Manai M, Finetti P, Mejri N, Athimni S, Birnbaum D, Bertucci F, Rahal K, Gamoudi A, Chaffanet M, Manai M, Boussen H.

Mol Clin Oncol. 2019 Feb;10(2):223-230. doi: 10.3892/mco.2018.1773. Epub 2018 Nov 26.

42.

Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?

Nicolas E, Bertucci F, Sabatier R, Gonçalves A.

Cancers (Basel). 2018 Dec 11;10(12). pii: E506. doi: 10.3390/cancers10120506. Review.

43.

Pathological grade-independent prediction of chemosensitivity by CINSARC should rehabilitate adjuvant chemotherapy in soft tissue sarcomas of any grade.

Bertucci F, Finetti P, Monneur A, Birnbaum D.

Ann Oncol. 2019 Feb 1;30(2):342-343. doi: 10.1093/annonc/mdy528. No abstract available.

PMID:
30535178
44.

Common origin of sequential cutaneous CD30+ lymphoproliferations with nodal involvement evidenced by genome-wide clonal evolution.

Xerri L, Adélaïde J, Avenin M, Guille A, Taix S, Bonnet N, Carbuccia N, Garnier S, Mescam L, Murati A, Chaffanet M, Coso D, Bouabdallah R, Bertucci F, Birnbaum D.

Histopathology. 2019 Mar;74(4):654-662. doi: 10.1111/his.13783. Epub 2019 Jan 31.

PMID:
30393995
45.

The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer.

Bertucci F, Finetti P, Simeone I, Hendrickx W, Wang E, Marincola FM, Viens P, Mamessier E, Ceccarelli M, Birnbaum D, Bedognetti D.

Br J Cancer. 2018 Nov;119(11):1383-1391. doi: 10.1038/s41416-018-0309-1. Epub 2018 Oct 24.

46.

The SCRIB Paralog LANO/LRRC1 Regulates Breast Cancer Stem Cell Fate through WNT/β-Catenin Signaling.

Lopez Almeida L, Sebbagh M, Bertucci F, Finetti P, Wicinski J, Marchetto S, Castellano R, Josselin E, Charafe-Jauffret E, Ginestier C, Borg JP, Santoni MJ.

Stem Cell Reports. 2018 Nov 13;11(5):1040-1050. doi: 10.1016/j.stemcr.2018.09.008. Epub 2018 Oct 18.

47.

Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer.

Guerin M, Gonçalves A, Toiron Y, Baudelet E, Pophillat M, Granjeaud S, Fourquet P, Jacot W, Tarpin C, Sabatier R, Agavnian E, Finetti P, Adelaide J, Birnbaum D, Ginestier C, Charafe-Jauffret E, Viens P, Bertucci F, Borg JP, Camoin L.

Oncotarget. 2018 Sep 18;9(73):33762-33777. doi: 10.18632/oncotarget.26031. eCollection 2018 Sep 18.

48.

Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype.

Harano K, Wang Y, Lim B, Seitz RS, Morris SW, Bailey DB, Hout DR, Skelton RL, Ring BZ, Masuda H, Rao AUK, Laere SV, Bertucci F, Woodward WA, Reuben JM, Krishnamurthy S, Ueno NT.

PLoS One. 2018 Oct 12;13(10):e0204513. doi: 10.1371/journal.pone.0204513. eCollection 2018.

49.

Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial.

Lebellec L, Bertucci F, Tresch-Bruneel E, Ray-Coquard I, Le Cesne A, Bompas E, Blay JY, Italiano A, Mir O, Ryckewaert T, Toiron Y, Camoin L, Goncalves A, Penel N, Le Deley MC.

BMC Cancer. 2018 Oct 11;18(1):963. doi: 10.1186/s12885-018-4828-1.

50.

EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinib.

Bouché O, Cesne AL, Rios M, Chaigneau L, Italiano A, Duffaud F, Lecomte T, Arsène D, Manfredi S, Aparicio T, Remy S, Isambert N, Collard O, Priou F, Bertucci F, Sambuc R, Bisot-Locard S, Bourges O, Chabaud S, Blay JY.

PLoS One. 2018 Sep 18;13(9):e0204117. doi: 10.1371/journal.pone.0204117. eCollection 2018.

Supplemental Content

Loading ...
Support Center